首页> 美国卫生研究院文献>Current Therapeutic Research Clinical and Experimental >Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40–80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5–10 mg: Open-Label Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies
【2h】

Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40–80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5–10 mg: Open-Label Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies

机译:最初未获氨氯地平5-10 mg控制的患者的替米沙坦40-80 mg加氨氯地平5或10 mg单药组合的长期耐受性和功效:长期开放标签随访TEAMSTA-5和TEAMSTA-10研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTwo 8-week, randomized, double-blind, controlled studies previously evaluated the efficacy and tolerability of single-pill combinations of telmisartan 40–80 mg/amlodipine 5–10 mg (T40–80/A5–10) in patients with hypertension not at diastolic blood pressure (DBP) goal (DBP <90 mm Hg) after 6 weeks of amlodipine 5 mg monotherapy (A5) (TEAMSTA-5) or amlodipine 10 mg monotherapy (A10) (TEAMSTA-10). The long-term (≥6 months) tolerability and efficacy of single-pill combinations of T40–T80/A5–A10 have now been evaluated in 2 open-label studies in patients who had successfully completed either TEAMSTA-5 or TEAMSTA-10 (TEAMSTA-5 and TEAMSTA-10 Follow-Ups).
机译:背景两项先前为期8周,随机,双盲,对照的研究评估了替米沙坦40–80 mg /氨氯地平5–10 mg(T40–80 / A5–10)的单药组合在非高血压患者中的疗效和耐受性氨氯地平5 mg单药(A5)(TEAMSTA-5)或氨氯地平10 mg单药(A10)(TEAMSTA-10)6周后达到舒张压(DBP)目标(DBP <90 mm Hg)。现在已在两项成功完成TEAMSTA-5或TEAMSTA-10的患者中进行的2项开放标签研究中评估了T40–T80 / A5–A10单药组合的长期(≥6个月)耐受性和疗效( TEAMSTA-5和TEAMSTA-10的后续行动)。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号